Aortic Aneurysm Repair Market Outlook:
Aortic Aneurysm Repair Market size was USD 4.5 billion in 2024 and is estimated to reach USD 9.9 billion by the end of 2037, expanding at a CAGR of 7.7% during the forecast period, i.e., 2025-2037. In 2025, the industry size of aortic aneurysm repair is evaluated at USD 4.8 billion.
The patient pool in the market is gradually expanding, owing to a surge in the aging population and a rise in the prevalence of cardiovascular disorders. As stated in an article published by the Centers for Disease Control and Prevention (CDC) in 2023, an estimated 200,250 latest cases of abdominal aortic aneurysms (AAA) have been diagnosed yearly in the U.S. In addition, more than 15,000 deaths have been caused due to the occurrence of ruptured AAAs. Besides, in 2022, the World Health Organization (WHO) estimated that heart diseases, including aortic aneurysm, effectively account for 33% of worldwide deaths, thus driving repair solutions demand and uplifting the market across different nations.
Furthermore, the global trade aspect in the market is readily dominated by Japan, Germany, and the U.S., combinedly accounting for almost 60.5% of exports. Besides, the U.S. also imports USD 1.4 billion worth of medical devices as of 2023, which includes catheter-based systems and stent grafts, mainly from Switzerland and Ireland. Meanwhile, assembly lines for such devices are efficiently automated, with robotics implementation that diminishes production duration by 25%. Moreover, research, development, and deployment funding are also substantial, with the National Institutes of Health (NIH) making an allocation of USD 465 million in 2023, thereby creating a positive impact on the market.
Aortic Aneurysm Repair Market - Growth Drivers and Challenges
Growth Drivers
-
Improvement and cost-effectiveness in health quality: There has been a constant shift in evidence-based treatment protocols that is significantly enhancing outcomes in the market. Regarding this, a clinical study was published by AHRQ in 2022, wherein early EVAR intervention diminished hospitalization by almost 30%, thus saving USD 1.1 billion in health and medical costs, especially in the U.S., within two years. Besides, the 2023 FDA report denoted that there has been a decline in 35-day post-op mortality to 2.6%, highly attributed to better patient monitoring and improved surgical techniques, thereby suitable for market upliftment.
-
Personal and government spending: This kind of spending is quite a trend, which denotes an optimistic outlook for the market. For instance, in 2023, Medicare expenditure on aortic aneurysm repair devices increased to USD 3.2 billion, which reflected a surge in the demand for minimally invasive EVAR procedures. Besides, out-of-pocket costs for average patients ranged from USD 3,550 per procedure, which has created financial gaps for underinsured individuals. Meanwhile, the 2022 U.S. Inflation Reduction Act has commenced capping yearly drug spending for the senior population, thus bolstering the market globally.
Historical Patient Growth for Evolution in the Aortic Aneurysm Market (2014-2024)
The market is experiencing transitions over the past decade, highly fueled by advancements in minimally invasive surgical innovation, enhanced diagnostics, and a rise in the aging population. In addition, the international patient pool between 2014 and 2024 has strengthened steadily, especially in developed economies, including Japan, Germany, and the U.S., where insurance coverage and screening programs have bolstered early detection. Meanwhile, developed nations, such as China and India, witnessed delayed but escalated growth, thus suitable for market upliftment across different nations.
Aortic Aneurysm Repair Patient Growth (2014-2024)
|
Country |
2014 |
2019 |
2024 |
CAGR (2014-2024) |
Key Growth Driver |
|
U.S. |
86 |
113 |
147 |
5.7% |
Medicare EVAR coverage expansion |
|
Germany |
43 |
59 |
80 |
6.6% |
Mandatory AAA screening (age 65+) |
|
France |
32 |
44 |
61 |
6.9% |
National vascular health initiative |
|
Spain |
19 |
26 |
38 |
7.5% |
Private hospital EVAR adoption |
|
Australia |
13 |
18 |
26 |
7.3% |
Government-funded rural diagnostics |
|
Japan |
69 |
90 |
117 |
5.6% |
Aging population (>30% seniors) |
|
India |
23 |
39 |
74 |
12.8% |
Rising hypertension & smoking rates |
|
China |
46 |
79 |
137 |
11.8% |
Urban hospital expansion |
Feasible Expansion Models Shaping the Market
The market is continuously evolving through tactical expansion models that have optimized revenue while overcoming domestic barriers. For instance, in developing nations, such as China and India, localized manufacturing processes and public-private partnerships have diminished expenses by 35%, thus further enabling wide implementation. Additionally, Japan and Germany have leveraged administrative-based screening programs, which have increased EVAR procedure volumes by an estimated 19.5% between 2020 and 2024. Besides, the U.S. effectively depends on Medicare reimbursements, with USD 2.9 billion spent on AAR devices, thus suitable for boosting the market.
Revenue Feasibility Models for AAR Market Expansion
|
Region |
Model |
Revenue Impact (2020-2024) |
Key Statistic |
|
India |
PPPs + Local Manufacturing |
14% Revenue Growth |
73,000 patients treated (2024) |
|
China |
Tiered Pricing + Urban Expansion |
USD 1.3 billion Market by 2025 |
136,000 patients (2024) |
|
U.S. |
Medicare Reimbursement Boost |
USD 2.9 billion Spend (2023) |
146,000 EVAR procedures (2024) |
|
Germany |
Mandatory Screening (Age 65+) |
19% Volume Increase |
79,000 patients (2024) |
|
Japan |
Robotics + AI Integration |
USD 905 million Revenue (2024) |
116,000 patients (2024) |
Challenges
-
Strict pricing strategies in developed economies: The aspect of administrative-mandated price ceilings in Europe and other emerging nations is creating significant profitability restraints in the market. Besides, the Institute for Quality and Efficiency in Health Care (IQWiG) in Germany has enforced stringent cost-effective thresholds, thus capping endovascular aneurysm repair (EVAR) device prices at around €12,550. These restrictions pressurize manufacturers and producers to limit research and development funding, especially in advanced technologies, thus negatively impacting the market.
-
Lengthy administrative pathways: The existence of prolonged approval duration in emerging economies increases development expenditure and causes delay in market entry, thus causing hindrance in the market. For instance, the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan effectively requires wide-ranging and localized clinical trials for devices that are already accepted in the EU and the U.S. However, Medtronic has readily diminished these delays by 45% by engaging the regulator and through parallel review strategies, thus suitable for market development.
Aortic Aneurysm Repair Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.7% |
|
Base Year Market Size (2024) |
USD 4.5 billion |
|
Forecast Year Market Size (2037) |
USD 9.9 billion |
|
Regional Scope |
|
Aortic Aneurysm Repair Market Segmentation:
Procedure Segment Analysis
The endovascular aneurysm repair (EVAR) segment is projected to hold the largest share of 73.7% in the aortic aneurysm repair market by the end of 2037. The segment’s growth is highly driven by superior clinical results and the implementation of a minimally invasive nature. Besides, in comparison to open surgical repair, EVAR not only diminishes hospital accommodation by approximately 62.5%, but also lowers 30-day mortality rates to 1.5%. The segment’s adoption is also escalated by private insurers and Medicare reimbursement services, which cover 86.5% of EVAR cases, owing to the cost-effectiveness factor, thereby uplifting the overall market.
Indication Segment Analysis
The abdominal aortic aneurysm segment is expected to hold the second-largest share of 66.8% in the aortic aneurysm repair market by the end of the forecast timeline. This growth stems from a surge in the aging population, along with a rise in screening programs. In this regard, the Preventive Services Task Force in the U.S. has recommended one-time ultrasound screening for at-risk men aged between 60 to 70 years, thus detecting an estimated 5.8% occurrence in the global demographic. However, approximately 27.5% of patients across different nations remain anatomically ineligible for suitable EVAR, thereby bolstering the market demand.
Our in-depth analysis of the global market includes the following segments:
|
Segment |
Subsegment |
|
Procedure |
|
|
Indication |
|
|
Product |
|
|
End User |
|
Vishnu Nair
Head- Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Aortic Aneurysm Repair Market - Regional Synopsis
North America Market Insights
North America is projected to be the dominant region in the aortic aneurysm repair market, with a share of 41.5% by the end of 2037. The market’s growth in the region is effectively driven by the presence of favorable reimbursement policies, along with robust health and medical infrastructure. Besides, the region’s 7.3% growth rate has reflected the comprehensive implementation of endovascular techniques, with EVAR processes expected to constitute almost 78.5% of repairs by 2030. Moreover, the U.S. readily dominates the region with an estimated 87%, while Canada is undergoing constraints, owing to disparities in provincial funding.
The aortic aneurysm repair market in the U.S. is significantly growing by grabbing 93% of the region’s EVAR procedures, which is highly supported by USD 3.2 billion from Medicare funding as of 2024, and 47% outpatient implementation rates. The screening initiative by the CDC has diminished rupture mortality by almost 32.5% since 2020, while private insurers currently provide 86% coverage for complicated fenestrated grafts. Besides, the NIH’s funding for research and development activities, accounting for USD 455 million in 2023, has accelerated next-generation stent development, with 13 latest devices gaining FDA acceptance in 2024, thus driving market growth.
The aortic aneurysm repair market in Canada is gaining increased exposure, with a growth rate of 5.9%. The component of fragmented provincial reimbursement is the ultimate factor behind this development, along with Ontario spending 2.8 times more per capita than Alberta. In addition, the federal health transfers have allocated USD 121 million for vascular care in 2024, but despite this, almost 38% of rural facilities in the country are devoid of operating rooms. However, to overcome this, Quebec’s mobile EVAR units serve approximately 15,200 patients every year, and an investment of USD 46 million by the BC for implementing robotic surgery systems is positively impacting the market.
Europe Market Insights
Europe in the aortic aneurysm repair market is expected to be the fastest-growing region with a share of 29.5% by the end of the forecast period. The market’s exposure in the region is highly fueled by standardized EVAR adoption as well as a rise in the aging population. Germany is effectively leading with €4.3 billion in expected revenue, catering for 33% of the share, which is followed by France with €2.9 billion, accounting for 22% of the share, and the UK with €3.1 billion, that is 19.5% share. Besides, the Medical Device Regulation (MDR) in the EU has escalated progression, with 47 newest stent grafts that have been approved between 2023 and 2024, thereby suitable for market expansion.
The aortic aneurysm repair market in Germany is dominating the region’s market with a 32.8% revenue share, accounting for €4.4 billion by the end of 2037. This is highly driven by the 95% EVAR adoption rate, along with a compulsory AAA screening program for men over 65 years old, which can detect almost 58,500 cases every year. Besides, the country’s €4.5 billion yearly spending on aortic care deliberately supports innovative technologies, including robotic-assisted EVAR, constituting 23% of rapid procedures, and bioresorbable stents, which are readily available through the €125 million Fraunhofer Society project.
The aortic aneurysm repair market in France is projected to capture an estimated 25% of the region’s market share, accounting for €2.9 billion during the forecast period. This is effectively fueled by the €2.2 billion yearly health budget allocation and the EVAR-First policy that is intended to reduce open surgeries by almost 55% since 2020. Additionally, the Plan Aneurysme initiative has increased screening for high-risk patients, which has further bolstered EVAR accessibility by 37.5%. Besides, the country is leading in telemedicine post-op monitoring, covering an estimated 67% of regional patients by the end of 2025.
Key Aortic Aneurysm Repair Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The international market is highly merged with Cook Medical, Gore, and Medtronic dominating with a joint share of 55%. These organizations have implemented certain strategies, including artificial intelligence integration, research and development activities for bioresorbable stents, and service expansion through localized manufacturing. For instance, in 2023, Medtronic entered into a partnership with the Mayo Clinic to successfully optimize stent size and reduce complications by almost 33%. Meanwhile, in the same year, W.L. Gore made an investment of €205 million by targeting 17% low reintervention rates, thereby denoting a prolific opportunity for the market upliftment.
Here is a list of key players operating in the global market:
|
Company Name (Country) |
Industry Focus |
Market Share (2024) |
|
Medtronic (Ireland/U.S.) |
Leading EVAR stent grafts (Endurant II), robotic-assisted systems |
23% |
|
W.L. Gore & Associates (U.S.) |
Pioneered EXCLUDER AAA stent grafts, specializes in PTFE-based devices |
19% |
|
Cook Medical (U.S.) |
Zenith Fenestrated grafts, focus on complex anatomies |
14% |
|
Boston Scientific (U.S.) |
Lotus Valve System, invests in bioresorbable stent R&D |
11% |
|
Abbott Laboratories (U.S.) |
XIENCE stent technology, expanding into AAA applications |
9% |
|
Terumo Corporation (U.S.) |
MicroVention neurovascular devices, branching into aortic repair |
xx% |
|
Endologix (U.S.) |
Ovation Prime stent graft system, targets outpatient EVAR |
xx% |
|
Lombard Medical (UK) |
Aorfix AAA stent grafts, specializes in flexible designs |
xx% |
|
JOTEC GmbH (Germany) |
E-vita thoracic stent grafts, leader in custom-made devices |
xx% |
|
CryoLife (U.S.) |
ProCol vascular grafts, focuses on hybrid repair solutions |
xx% |
|
Braile Biomédica (Brazil) |
Dominates LATAM market with low-cost stent grafts |
xx% |
|
Cardiatis (Belgium) |
Multilayer Flow Modulator for complex aneurysms |
xx% |
|
Artivion (U.S.) |
CryoValve SG pulmonary graft, expanding into TAA repair |
xx% |
|
Endospan (Israel) |
NEXUS aortic arch stent graft system, innovating in branched designs |
xx% |
|
Meril Life Sciences (India) |
myVal THV, emerging as cost-effective alternative in Asia |
xx% |
Below are the areas covered for each company in the market:
Recent Developments
- In May 2025, Endospan Ltd. accomplished USD 85 million Series D funding, which was led by OrbiMed to ensure the marketing of the NEXUS Aortic Arch Stent Graft System in Europe, with implants displaying almost 100% patency.
- In February 2025, JOTEC GmbH declared that the E-vita OPEN NEO thoracic stent graft has received UKCA marking, which features a fusion design by combining endovascular components with a surgical graft for single-stage frozen elephant trunk procedures.
Author Credits: Radhika Pawar
- Report ID: 7817
- Published Date: Jun 26, 2025
- Report Format: PDF, PPT
